Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial

Globally, about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection. A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples. The HPV-16/18 AS04-adjuvanted vaccine Cervarix(®)* has shown a high level of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Feng-Cai, Li, Chang-Gui, Pan, Hong-Xing, Zhang, Yi-Ju, Bi, Dan, Tang, Hai-Wen, Datta, Sanjoy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013406/
https://www.ncbi.nlm.nih.gov/pubmed/21801604
http://dx.doi.org/10.5732/cjc.010.10564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013406/
https://www.ncbi.nlm.nih.gov/pubmed/21801604
http://dx.doi.org/10.5732/cjc.010.10564

Ejemplares similares